Novartis

Mar 28, 2023

Novartis Announces the Positive Results of Phase III NATALEE Trial Evaluating Kisqali; FDA Approves Pharming’s Joenja for APDS; FDA Orphan Drug Designation to Cyclerion’s Zagociguat; Iovance Completes BLA Submission for Lifileucel in Advanced Melanoma; BPGbio Announces Partnership with debra of America

Jan 31, 2023

Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval

Aug 25, 2021

Top 7 Pharma Industry Leaders in 2020 By the Numbers

Jun 28, 2021

Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future

Jun 21, 2021

How will Pharmacotherapies help the growing number of Presbyopes?

Apr 08, 2021

Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M

Apr 02, 2021

A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers

Mar 25, 2021

Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Feb 26, 2021

Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore!

Feb 15, 2021

The Paradox of Rare: Chalking out Challenges in the Rare Disease Market

Newsletter/Whitepaper